<![CDATA[Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC]]>

Data ReadoutpositiveatezolizumabmFOLFOX6bevacizumabPositive

AI Analysis

Summary

Atezolizumab combined with mFOLFOX6 and bevacizumab demonstrated a 58% reduction in progression or death risk compared to atezolizumab alone in dMMR/MSI-H metastatic colorectal cancer patients.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Atezolizumab plus mFOLFOX6 and bevacizumab reduced risk of progression or death by 58% versus atezolizumab alone in dMMR/MSI-H metastatic colorectal cancer

Importance:6/10

Sentiment:

0.70

oncologycolorectal cancerimmunotherapycombination therapyPFSdMMRMSI-H

Related Companies

$RHHBY

Read the original article

Published by Cancer Network on July 30, 2026 3:30 PM

Read Original